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Edited by Jesus AvilaAbstract Dysfunction of proteasome contributes to the accu-
mulation of the abnormally hyperphosphorylated tau in Alzhei-
mer’s disease. However, whether tau hyperphosphorylation and
accumulation aﬀect the activity of proteasome is elusive. Here
we found that a moderate tau phosphorylation activated the tryp-
sin-like activity of proteasome, whereas further phosphorylation
of tau inhibited the activity of the protease in HEK293 cells sta-
bly expressing tau441. Furthermore, tau hyperphosphorylation
could partially reverse lactacystin-induced inhibition of protea-
some. These results suggest that phosphorylation of tau plays a
dual role in modulating the activity of proteasome.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
Keywords: Alzheimer disease; Tau; Phosphorylation;
Proteasome1. Introduction
Alzheimer’s disease (AD) is characterized by the formation
of neuroﬁbrillary tangles (NFTs) and senile plaques. NFTs
are primarily composed of the abnormally hyperphosphoryl-
ated tau that forms paired helical ﬁlaments (PHFs) [1–3]. For-
mation of NFTs is closely correlated with the temporal and
spatial progression of AD pathology and other tauopathies
[4,5]. The ﬁnding of tau mutations in frontotemporal dementia
suggests that abnormal tau metabolism might be an initial fac-
tor leading to tauopathies [6]. The regulation of tau hyper-
phosphorylation has been well studied and it is known that
the disturbance of protein kinase and protein phosphatase sys-
tem [7] plays a major role in this process. Among various ki-
nases and phosphatases, protein kinase A (PKA) [8,9],
protein phosphatase 1 (PP1) and PP2A [10–14] are among
the most implicated in the abnormal hyperphosphorylation
of tau.Abbreviations: AD, Alzheimer’s disease; NFT, neuroﬁbrillary tangle;
HEK293, human embryonic kidney cell; MTT, 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide thiazolyl blue; BCA, bicin-
choninic acid; PKA, protein kinase A; PP1, protein phosphotase 1;
PP2A, protein phosphotase 2A; OA, okdaic acid
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doi:10.1016/j.febslet.2007.02.065Proteasome system plays a pivotal role in clearing the mis-
folded proteins [15] and thus maintains intracellular homeosta-
sis of proteins [16,17]. Compared with age-matched controls,
the activity of proteasome is decreased in the AD brains
[18,19], which correlates to the increased level of NFTs
[20,21]. Tau protein is a substrate of proteasome both
in vitro and in vivo [22,23]. In NFTs, the accumulated tau pro-
teins are not only hyperphosphorylated but also ubiquitinated,
suggesting that the dysfunction of proteasome also contributes
to formation of NFTs [24,25]. It is reported recently that the
AD-like hyperphosphorylation of tau could serve as a signal
for tau ubiquitination in vitro and in culture cells [6]. Until
now, it is still not clear how proteasome activity is impaired
in the AD brains.
In the present study, we have investigated whether hyper-
phosphorylation and accumulation of tau aﬀect the activity
of proteasome in human embryonic kidney cells (HEK293)
stably expressing tau441 or its pcDNA vector. The hyper-
phosphorylation and accumulation of tau were induced by for-
skolin, a speciﬁc activator of PKA [26,27] or okadaic acid
(OA), a speciﬁc inhibitor of PP1/2A [28], and then, the rela-
tionship between tau phosphorylation/accumulation and pro-
teasome activity was analyzed. Our results demonstrated that
moderate tau phosphorylation could activate the activity of
proteasome, but further hyperphosphorylation/accumulation
of tau inhibited the proteinase.2. Materials and methods
2.1. Antibodies and chemicals
Rabbit polyclonal antibodies (pAb) PS214 and PS262 against phos-
phorylated tau at Ser-214 and Ser-262 were purchased from BIO-
SOURCE International (Camarillo, CA). Rabbit pAb to 20S
proteasome subunit b2 was from Aﬃniti Research Products (Biomol
International LP, Plymouth meeting, PA). Monoclonal antibodies
(mAb) PHF-1 detecting tau phosphorylated at Ser-396/Ser-404 was a
gift from Dr. Peter Davies (Albert Einstein College of Medicine,
Bronx, NY). mAb Tau-1 detecting dephosphorylated tau at Ser-198/
Ser-199/Ser-202 (Chemicon International Inc., Temecula, CA, USA),
mAb Tau-5 reacting with total tau was from Lab Vision Corp
(Fremont, CA) and mAb b-actin was from Santa Cruz (Santa Cruz,
CA). Forskolin, OA, lactacystin and Boc-Leu-Ser-Thr-Arg-7-amino-
4-methyl coumarin were from Calbiochem (San Diego, CA). Horse-
radish peroxidase-conjugated secondary antibodies and Rhodamine
Red-X-conjugated goat anti-rabbit IgG (H + L) were from Pierce
Chemical Co. (Rockford, IL) and Molecular Probes company
(Eugene, OR, USA), respectively. Chemiluminescent substrate kit
was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), Lipofect-
amine 2000 was from Invitrogen (Carlsbad, CA). 3-(4, 5-Dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide thiazolyl blue (MTT) and
thioﬂavin-S were from Sigma (St. Louis, MO). OA, forskolin andation of European Biochemical Societies.
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concentration of DMSO during drug treatments was maintained in
0.1%, which was used as vehicle control.2.2. Cell culture and selection of tau stab cell line
Wild-type HEK293 cells were cultured in DMEM supplemented
with 10% fetal bovine serum and maintained in 37 C and 5% CO2.
HEK293 cells were stably transfected tau441 (HEK293/tau441) using
Lipofectamine 2000 according to the manufacturer’s instructions. Sin-
gle cell clones were selected by using 250 lg/ml of G418 and the expres-
sion of the target genes were conﬁrmed by Western blot.2.3. Assays of cell viability
Cell viability after treatment with forskolin for 2 h or OA for 24 h
was measured by MTT assay. Brieﬂy, HEK293/tau441 cells were
seeded in 96-well tissue-culture plates in 100 ll media and cultured
for 48 h. The cells were then exposed to diﬀerent concentrations (0.5,
1, 2 and 4 lM) of forskolin for 2 h or OA (10, 20, 30, 40, 50 and
60 nM) for 24 h, and then 10 ll MTT (5 mg/ml in phosphate-buﬀeredA
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Fig. 1. Eﬀect of forskolin on tau phosphorylation. HEK293 cells stably expre
and the phosphorylation of tau was measured by Western blotting. The phos
indicated was normalized by total level of tau probed by Tau-5. Note: as T
immunoreaction represents hyperphosphorylation of tau at this epitope. The
was shown. *P < 0.05, **P < 0.01 vs. control, # P < 0.05 vs. 2 lM group.saline, PBS) was added to each well and incubated at 37 C for 3 h. The
cells were permeabilized with 100 ll (10%, w/v) SDS in 0.01 N hydro-
chloric acid and incubated at 37 C for overnight. The plates were read
for light absorbance at 570 nm and the results expressed as the percent-
age of control samples.
2.4. Western blotting
The phosphorylation of tau at various sites was determined by Wes-
tern blotting. The total proteins from the cultures were extracted with
RIPA buﬀer [50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 0.5% (w/v)
sodium deoxycholate, 1% (v/v) NP-40, 0.1% (w/v) SDS, 100 lM
sodium orthovanadate, 1 mM phenylmethysulfonyl ﬂuoride and
1 lg/ml protease inhibitor cocktail containing leupeptin, aprotinin
and pepstatin]. The cell lysates were boiled, sonicated brieﬂy and cen-
trifuged at 12500 · g for 15 min. Protein concentration in the superna-
tants was determined using the bicinchoninic acid (BCA) Protein
Assay Kit (Pierce, Cheshire, UK) with the bovine serum albumin as
the standard. Equal amounts of proteins were isolated on 10% SDS–
polyacrylamide gel (SDS–PAGE) and transferred to nitrocellulose
membranes (Hybond C-Super, Amersham Pharmacia Biotech,B
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Q.-G. Ren et al. / FEBS Letters 581 (2007) 1521–1528 1523Amersham, UK). The membranes were blocked in 5% (w/v) nonfat
milk in TTBS (10 mM Tris–HCl, 150 mM NaCl, 0.02%(v/v) Tween-
20, pH 7.5) and probed with PS214 (1:1000) or PS262 (1:500) or
Tau-1 (1:30000) or PHF-1 (1:500) or Tau-5 (1:2000) or b2 (1:500) or
b-actin (1:500) overnight at 4 C. The blots were developed with horse-
radish peroxidase-conjugated secondary antibodies (1:5000) and visu-
alized by enhanced chemiluminescent substrate kit and exposure to
CL-XPosure ﬁlm. The immunoreactivity of tau bands was quantita-
tively analyzed by Kodak Digital Science 1D software (Eastman Ko-
dak Co., New Haven, CT) and expressed as mean optical density.
The levels of total tau and phosphorylated tau at various sites were ex-
pressed as relative level of the mean optical density against control,
and the phosphorylated level of tau was normalized to total tau.
2.5. RT-PCR
Total cellular RNA was extracted using Trizol according to man-
ufacture’s instruction (ThermoScript kit, Invitrogen, Carlsbad, CA).
Brieﬂy, 3 lg of total RNA was incubated with AMV reverse transcrip-
tase (0.5 U) in 25 ll buﬀer containing random primers, dNTPs and
protease inhibitor. Then, the cDNA transcripts (1 ll) were used for
PCR ampliﬁcation with 1 U TaqDNA polymerase in buﬀer containing
1.5 mM Mg, 0.4 mM dNTPs and 1 lM primer. The sequence of the
primers for proteasome PA28a was 5 0-AGATCCGCAATGCTTAT-
GTG-30 (sense) and 3 0-ATTCCCACTGTTTCGAGTCG-50 (anti-
sense). The sequence of the primers for proteasome subunit b2 was
5 0-ACGGCAGCAGCTAACTTCAC-30 (sense) and 3 0-GTAGGACT-
TAGACGGTTGGA-50 (antisense). The PCR products were resolved
on 1.5% agarose gel and visualized by ethidium bromide staining.
2.6. Thioﬂavin-S staining and immunocytochemistry
Thioﬂavin-S staining was performed as reported previously [29].
Brieﬂy, the cells were cultured on coverslips for 48 h and then subjected
to forskolin for 2 h. After ﬁxation with cold methanol for 5 min and
permeabilized with 0.5% Triton X-100 for 10 min, the coverslips were
incubated overnight at 4 C with PS214 (1:300) and developed with
tetramethylrhodamine isothiocyanate-conjugated secondary antibody
(1:800) for 1 h. Before mounting, the coverslips were immersed in
0.005% thioﬂavin-S solution (w/v, in 50% ethanol) for 5 min.
2.7. Assay of proteasome activity
The proteasome activity was measured as described previously [30].
After washing with PBS, the cells were resuspended with buﬀer con-
taining 12.5 mM KCl, 135 mM Tris-acetate, pH 7.5, 80 mM EGTA,
6.25 mM b-mercaptoethanol, and 0.17% octyl-b-D-glucopyranoside.
After centrifugation at 12500 · g for 15 min at room temperature,
the supernatant was collected and protein concentration was deter-
mined by Bradford method [31]. To determine trypsin-like activity of
proteasome, 100 lg of proteins was incubated for 30 min at 37 C with
100 ll of 100 mM HEPES–HCl (pH 7.5) buﬀer containing 50 lM of
substrate (Boc-Leu-Ser-Thr-Arg-7-amino-4-methyl coumarin), the
reaction was terminated by addition of 100 ll of 220 mM sodium ace-
tate buﬀer and placed for 30 min at 4 C. The precipitated non-de-
graded protein was separated at 400 g for 30 min at 4 C and 200 ll
aliquot of the supernatant was mixed with 2 ml of distilled water. Fluo-
rescence of the sample was measured with F-4500 spectroﬂuorometer
(Sigma) at 370 nm excitation and 430 nm emission wavelengths.
2.8. Statistical analysis
Data were analyzed with SPSS statistical software. The one-way
analysis of variance procedure followed by least signiﬁcant diﬀerence
post hoc tests was used to determine the statistical signiﬁcance of dif-
ferences of the means.0 Con 0.5 1 2 4
Forskolin (μM)
Fig. 2. Eﬀect of forskolin-induced tau hyperphosphorylation on
proteasomal activity and cell viability. HEK293 cells stably expressing
tau441 (HEK293/tau441) or its pcDNA vector (HEK293/vec) were
treated with 0.5, 1, 2 or 4 lM forskolin for 2 h and then the trypsin-like
activity of proteasome was measured by using Boc-Leu-Ser-Thr-Arg-7-
amino-4-methyl coumarin as a substrate. The HEK293/vec cell does
not express endogenous tau. The cell viability was measured by MTT
assay. * P < 0.05, ** P < 0.01 vs. control.3. Results
3.1. Relationship between forskolin-induced tau
hyperphosphorylation and proteasome activity
To induce tau hyperphosphorylation, we treated the
HEK293 cells stably expressing tau protein (HEK293/
tau441) with 0.5, 1, 2 and 4 lM of forskolin for 2 h. Compared
with controls, the level of the phosphorylated tau increased,respectively, to 3.2-, 4.0-, 4.5- and 5.3-folds at Ser-214
(Fig. 1A), and to 1.6-, 2.0-, 2.5- and 3.0-folds at Ser-262
(Fig. 1B), and to 1.5-, 1.6-, 1.9- and 2.8-folds at Ser-396/
404 (Fig. 1C) after treatment with 0.5, 1, 2 and 4 lM of for-
skolin. The immunoreactivity of Tau-1 decreased to 82% and
75% of the control level upon 2 and 4 lM of forskolin treat-
ment, which represents a gradual increase of tau phosphoryla-
tion at Ser-198/199/202 sites (Fig. 1D). The level of total tau
measured by Tau-5 was not altered obviously upon forskolin
treatment (Fig. 1E). These data conﬁrmed that forskolin
induced tau hyperphosphorylation at multiple AD sites with
a dose-dependent manner.
To investigate the eﬀect of tau hyperphosphorylation on
proteasome, we measured the trypsin-like activity of protea-
some using Boc-Leu-Ser-Thr-Arg-7-amino-4-methyl coumarin
as a substrate in the cells treated with diﬀerent concentrations
of forskolin. We observed that the proteasome activity in-
creased dose-dependently when the cells were treated with
0.5, 1 and 2 lM of forskolin (Fig. 2A). However, when the
concentration of forskolin was reached to 4 lM, the activity
of proteasome was signiﬁcantly suppressed (Fig. 2A). To con-
ﬁrm the role of tau and exclude the eﬀect of forskolin itself on
the activity of proteasome, we treated the control cells stably
expressing pcDNA vector (HEK293/vec) which does not ex-
press endogenous tau, with the same concentrations of for-
skolin for 2 h. No obvious change in proteasome activity
was observed in the HEK293/vec cells upon forskolin treat-
ment (Fig. 2A). The cell viability was measured by MTT assay
and no change was detected upon treatment of forskolin
1524 Q.-G. Ren et al. / FEBS Letters 581 (2007) 1521–1528(Fig. 2B), which ruled out the possible inﬂuence of the altered
cell viability on tau phosphorylation and proteasome activity.
The above data together suggest that tau phosphorylation may
play a dual role in aﬀecting the activity of proteasome, i.e.,
moderate phosphorylation may promote the activity of protea-
some, but when the phosphorylation of tau reaches to certain
level, it inhibits the proteasome.
3.2. Relationship between OA-induced tau hyperphosphorylation
and proteasome activity
To further verify the eﬀect of tau phosphorylation on the
proteasome activity, we used OA, a protein phosphatase inhib-
itor, to induce tau hyperphosphorylation in HEK293/tau441.
We found that treatment of the cells with 10, 20 or 30 nM of
OA for 24 h did not alter the phosphorylation level of tau at
Tau-1 and PS262 sites (not shown). Then, we adjusted the con-
centration of OA to 40, 50 and 60 nM. Compared with
untreated controls, the level of the phosphorylated tau
increased to 1.5-, 2.1- and 3.2-folds at Ser-262 (Fig. 3A) and
it was increased to 1.3-, 1.7- and 2.7-folds at PHF-1 epitopeA
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Fig. 3. Eﬀect of okadaic acid on tau phosphorylation and cell viability. (A,
were treated with 40, 50 or 60 nM okadaic acid (OA) for 24 h and then
phosphorylation of tau at PHF-1, PS262 and Tau-1 epitopes was normalized
MTT assay. *P < 0.05, **P < 0.01 vs. control, #P < 0.05 vs. 50 nM group.(Fig. 3B) after treatment with 40, 50 and 60 nM of OA, respec-
tively. The level of unphosphorylated tau at Tau-1 epitope de-
creased to 76%, 69% and 49% of the control level (Fig. 3C),
representing an increased phosphorylation of tau at Tau-1
sites. The treatment of the cells with OA changed neither the
total level of tau (Fig. 3D) nor the cell viability measured by
MTT assay (Fig. 3E).
We then measured the proteasome activity in HEK293/vec
and HEK293/tau441 cells exposed to OA for 24 h. Compared
with the untreated control, the proteasome activity increased
to 1.3-folds after treatment with 40 nM of OA. However, when
the OA concentration was further increased to 60 nM, the pro-
teasome activity was decreased to 74.2% of the control level
(Fig. 4A). No evident change in proteasome activity was de-
tected at low OA concentrations (10, 20 and 30 nM) in
HEK293/tau441 cells. Additionally, no obvious alteration of
the proteasome activity was detected at various concentrations
of OA-treated HEK293/vec cells (Fig. 4A). These results fur-
ther verify the dual eﬀects of tau phosphorylation on protea-
some activity.B
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some activity. (A) HEK293 cells stably expressing tau441 (HEK293/
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30, 40, 50 or 60 nM OA for 24 h, and then the trypsin-like activity of
proteasome was measured by using Boc-Leu-Ser-Thr-Arg-7-amino-4-
methyl coumarin as a substrate. (B) The HEK293/tau441 were
incubated with 5 lM of lactacystin for 30 min followed by treatment
of 40 nM OA for 24 h, and the trypsin-like activity of proteasome was
measured by using Boc-Leu-Ser-Thr-Arg-7-amino-4-methyl coumarin
as a substrate. *P < 0.05, **P < 0.01 vs. control, ##P < 0.05 vs.
lactacystin group.
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ity was further sustained by the following study: we treatedB
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forskolin for 2 h. The protein level of proteasome was measured by Western b
detected by RT-PCR.HEK293/tau441 cells for 24 h with OA and lactacystin, an irre-
versible inhibitor of 20S proteasome [32]. It was shown that
OA (40 nM) alone increased the proteasome activity to 1.3-
folds, while lactacystin (5 lM) alone for 30 min decreased
the proteasome activity to 28% of the control level. However,
this inhibition of proteasome by lactacystin was restored to
47% of the control level when the cells were further incubated
with 40 nM of OA for 24 h (Fig. 4B). These results suggest that
phosphorylation of tau induced by OA can partially reverse
the lactacystin-induced inhibition of the proteasome activity.
As OA does not aﬀect the activity of proteasome in vector-
transfected cells as shown in Fig. 4A, the results further
support the role of tau phosphorylation in manipulating the
activity of proteasome.3.3. The possible underlying mechanisms for the alterations of
proteasome activity
To study the mechanism of tau phosphorylation in leading
to this peculiar alteration of the proteasome activity, we ﬁrstly
measured the expression levels of proteasome mRNA (b2 sub-
unit and PA28a) and the protein (b2 subunit) by RT-PCR and
Western blotting. No obvious change was observed (Fig. 5),
suggesting that the alteration of proteasome activity induced
by tau phosphorylation was not due to the expression of the
enzyme.
Then, we detected the aggregation of the hyperphosphoryl-
ated tau by co-labeling of thioﬂavin-S with PS214. We ob-
served that the thioﬂavin-S was dimly co-labeled with
background staining of PS214 in the untreated HEK293/
tau441 cells and in cells treated with 0.5 or 1 lM of forskolin
for 2 h; the thioﬂavin-S staining was slightly increased with an
obviously enhanced PS214 staining when the cells were treated
with 2 lM of forskolin, and signiﬁcantly increased staining of
thioﬂavin-S and PS214 was observed when the cells were trea-
ted with 4 lM of forskolin (not shown). These data suggest
that aggregation of the hyperphosphorylated tau may be in-
volved in the inhibition of proteasome activity.0
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stably expressing human tau441 were treated with 0.5, 1, 2 or 4 lM
lotting, and the mRNA level of proteasome subunit b2 and PA28 a was
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Formation of neuroﬁbrillary tangles in the involved neurons
is a recognized neuropathological hallmark of AD and other
tauopathies [1–3]. Therefore, understanding the mechanisms
leading to the formation of tau inclusions is pivotal in disclos-
ing the pathogenesis and designing the strategies to arrest the
pathological process. Previous studies strongly suggest that
in addition to hyperphosphorylation, dysfunction of protea-
some may also play a crucial role in the accumulation of tau
protein in the AD brains: the hyperphosphorylated tau in
the inclusion body of the AD brain is ubiquitinated which in-
volves proteasome [24,33]; the activity of proteasome is re-
duced in the vulnerable regions of the AD brain [18,19]. It is
not clear what may be the upstream eﬀectors which impair
the activity of proteasome in vivo. Microtubule-associated
protein tau is a substrate of proteasome [22,23]. A previous
study demonstrated that the in vitro aggregation of tau could
inhibit the activity of proteasome [34]. In this study, we inves-
tigated whether tau phosphorylation could inﬂuence the activ-
ity of proteasome. We observed in HEK293 cells that tau
phosphorylation plays a dual role in mediating the activity
of proteasome, i.e., phosphorylation of tau to a certain extent
activates proteasome but further phosphorylation inhibits the
protease. We conﬁrmed the role of tau in modulating the pro-
teasome by using a vector-transfected cell line, which did not
express tau. Tau is substrate of proteasome [22,23]. We also
observed that the total level of tau probed by Tau-5 was not
changed with the change of proteasome activity. Previous
studies have demonstrated that the eﬀect of proteasome on
tau degradation is aﬀected by the phosphorylation status of
tau, for instance, hyperphosphorylation makes tau a less eﬃ-
cient substrate to proteasome [35], which is not the case for
the non-phosphorylated tau. Furthermore, diﬀerent site-phos-
phorylated tau also has diﬀerent response to the proteasome.
For example, we have observed previously that inhibition of
proteasome leads to accumulation of the phosphorylated tau
at multiple sites [23], but it decreases the level of Ser214-phos-
phorylated tau (unpublished data). Therefore, we speculate
that the unchanged total level of tau observed in our system
may be the consequence from a counteractive eﬀect of the
phosphorylated and non-phosphorylated tau (or diﬀerent sites
phosphorylated tau) to the proteasome.
The proteasome contains three diﬀerent active subunits
namely b5, b2, and b1 which respectively mediate the post-
acidic-, tryptic-, and chymotryptic-activities of the proteasome
[36–38]. PA28a is a subunit of 11S regulator of proteasome
which stimulates the peptidase activity of the 20S proteasome
[39]. To understand the possible underlying molecular mecha-
nism for the alterations of proteasome induced by tau phos-
phorylation, we ﬁrstly measured the levels of mRNA and
protein subunits (b2 and PA28a) of proteasome, but no change
was detected after treatment of the cells with forskolin. These
results exclude the possibility that the phosphorylated tau af-
fects proteasome activity by increasing the expression of pro-
teasome. The proteasome is the major proteolytic system
responsible for the removal of misfolded or impaired proteins
[40]. Previous studies demonstrated that the activity of protea-
some was increased in response to multiple environment stim-
uli, such as cytokines IFN-c or TNF-a produced by T cells
during an acute immune response [41–43]. It was also demon-
strated that the proteasome activity was upregulated throughbinding of the 11S regulatory subunit to the proteasome or
activation of poly-ADP-ribose polymerase upon moderate oxi-
dative stress [44,45]. Such plasticity would allow the cells to
cope with the multiple stresses and thus to maintain a proper
intracellular homeostasis. In our study, phosphorylation of
tau at some of the AD-related sites to a certain degree might
act as a stress moderator to provoke the activation of protea-
some, and so that the activated proteasome could degrade the
excessively phosphorylated tau in the cells.
Then, why was the proteasome activity inhibited when 4 lM
of forskolin or 60 nM of OA were used in tau transfected cells?
To answer this question, we ﬁrstly analyzed the diﬀerences of
the phosphorylation level of tau between the boundaries of
the treatments. We found that the phosphorylated tau was sig-
niﬁcantly higher (P < 0.05) in cells treated with 4 lM of for-
skolin or with 60 nM of OA than those treated with lower
concentrations of the compounds. These data suggest that
the signiﬁcantly elevated tau phosphorylation induced by
4 lM of forskolin or 60 nM of OA may play a role in turning
the proteasome from activation to inhibition. We also detected
the aggregation of the phosphorylated tau by co-labeling stain-
ing. Compared with the cells treated with 2 lM forskolin, we
found that treatment of 4 lM forskolin resulted in a signiﬁ-
cantly increased aggregation of the Ser214-phosphorylated
tau, which was co-labeled with an enhanced thioﬂavin-S stain-
ing (not shown). This result suggested that excessive phosphor-
ylation of tau protein might render them more vulnerable to
form aggregates and thus inhibits the activity of proteasome,
which was proposed previously [34,46,47]. We also noticed
that the proteasome activity did not show a linear increase
with the linearly increased tau phosphorylation upon forskolin
treatment. We speculate that it is the phosphorylation-induced
structural change (such as aggression) but not the phosphory-
lation itself of tau aﬀects the activity of proteasome. This point
is also supported by our observation that the proteasome
activity did not decrease further when we used 8 lM of for-
skolin, though the phosphorylation of tau was further in-
creased at this condition (not shown).
Taken together, we have demonstrated in the present study
that tau phosphorylation modulates the activity of protea-
some. Furthermore, a moderate phosphorylation of tau acti-
vates proteasome, but further phosphorylation/accumulation
of tau inhibits the activity of the enzyme. It suggests that the
proteasome dysfunction may be a consequence of tau hyper-
phosphorylation in the development of AD. Therefore, arrest-
ing tau hyperphosphorylation may be critical in inhibiting the
evolution of the disease.
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